



Weiland, Florian; Martin, Karina; Oehler, Martin Klaus; Hoffmann, Peter  
Deciphering the molecular nature of ovarian cancer biomarker CA125, International Journal of Molecular 
Sciences, 2012; 13(8):10568-10582. 
 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed 



























All articles published by MDPI are made available under an open access license worldwide immediately. 
This means: 
 
• everyone has free and unlimited access to the full-text of all articles published in MDPI journals, 
and 
• everyone is free to re-use the published material given proper accreditation/citation of the original 
publication. 
• open access publication is supported by authors' institutes or research funding agency by 





15th January 2013 
Int. J. Mol. Sci. 2012, 13, 10568-10582; doi:10.3390/ijms130810568 
 





Deciphering the Molecular Nature of Ovarian Cancer 
Biomarker CA125 
Florian Weiland 1,†, Karina Martin 1,†, Martin K. Oehler 2 and Peter Hoffmann 1,* 
1 Adelaide Proteomics Centre, School of Molecular and Biomedical Science, University of Adelaide, 
Adelaide, SA 5005, Australia; E-Mails: florian.weiland@adelaide.edu.au (F.W.); 
karina.martin@adelaide.edu.au (K.M.) 
2 Research Centre for Reproductive Health, Robinson Institute, University of Adelaide,  
Adelaide, SA 5005, Australia; E-Mail: martin.oehler@adelaide.edu.au 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: peter.hoffmann@adelaide.edu.au;  
Tel.: +61-8-8313-5507; Fax: +61-8-8313-4362. 
Received: 2 July 2012; in revised form: 3 July 2012 / Accepted: 13 August 2012 /  
Published: 22 August 2012 
 
Abstract: The ovarian cancer biomarker CA125 has been extensively investigated over the 
last 30 years. The knowledge about the exact molecular nature of this protein, however, 
remains fragmented. This review provides an overview of the structural research regarding 
CA125, and presents an orthogonal verification method to confirm the identity of this 
molecule. The need for independent identification of CA125 is exemplified by several 
reports where mutually exclusive data concerning the existence of isoforms and the  
glycan moieties is presented. Mass spectrometry can overcome the pitfalls of a single 
detection/identification method such as antibody probing. Independent verification of 
CA125 identity in characterization studies will help establish a refined model of its 
molecular structure that will promote the development of new approaches for diagnosis, 
prognosis and therapy of ovarian cancer. 








The discovery of CA125 represented a milestone for ovarian cancer detection. In 1981, Bast et al. 
identified a murine monoclonal antibody, OC125, which reacted almost exclusively with ovarian 
cancer cell lines and cryo-preserved tissue of ovarian cancer patients [1]. An immuno assay for the 
detection of the OC125 antigen (CA125) in serum was soon developed and demonstrated a significant 
correlation between CA125 expression levels and the regression, stability or progression of epithelial 
ovarian carcinomas [2]. However, elevated serum concentrations were also found in 29% of patients 
with non-gynecological cancers as well as individuals presenting with benign conditions such as 
endometriosis, menstruation and pregnancy [2,3]. Due to the lack of specificity of CA125 a risk of 
malignancy index (RMI) is commonly used in clinical practice which combines CA125 levels, 
ultrasonographic findings and menopausal status of the patient. Using this approach 85% sensitivity 
and 97% specificity can be achieved when distinguishing benign from malignant ovarian disease [4]. 
However, this is not a suitable screening strategy for ovarian cancer as this disease has a low 
prevalence and requires a specificity of more than 99.6% to achieve an acceptable positive predictive 
value of 10% [5]. A large randomized controlled trial (RCT) of ovarian cancer screening (OCS) which 
is ongoing in the United Kingdom, involving 200,000 postmenopausal women (UK Collaborative Trial 
of Ovarian Cancer Screening, UKCTOCS, www.ukctocs.org) in a multimodality approach, estimates a 
woman’s risk of ovarian cancer (ROC) [6]. Here, an estimate on the basis of age and modified by the 
relative fit of the serial CA125 profile to the change-point model estimated from known cases is compared 
with the flat profile model estimated from known controls. Women who are found to have a high ROC 
then undergo screening by transvaginal ultrasonography. Preliminary results are promising but it 
remains unknown if this multimodality screening with CA125 will improve disease specific mortality.  
In order to improve detection, considerable research has been directed at furthering the 
understanding of the functional and biochemical nature of CA125. Three decades of research unveiled 
the partial nucleotide and amino acid sequence, cellular localization and secretion, oligosaccharide 
structures and possible biological roles of CA125 during cancer and normal conditions. Unfortunately, 
the presented data is incomplete and contradictory. In many cases it is difficult to draw conclusions 
from the reports.  
This article summarizes the currently available published data and conflicting views on the 
molecular nature of CA125. As this ambiguity may arise from antibody cross-reactivity, an orthogonal 
method of protein identification is required. Several studies employ mass spectrometry (MS) to 
independently verify antibody based CA125 detection. However, currently published mass spectrometric 
data does not satisfy established protocols and could therefore be unreliable. This highlights the need 
for high quality mass spectrometric data to enable reliable CA125 identification. Ultimately, the 
revised knowledge about the nature of CA125 may lead to the development of quantification 
techniques that will increase current sensitivities and specificities of ovarian cancer diagnosis, 
prognosis and progression. 
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2. Biological Function 
The biological role for CA125 is still under investigation though several studies have demonstrated 
a relationship between CA125 and the immune system. In 2003 Kui Wong et al. proposed a role in 
immunity based upon the characterization of the N-oligosaccharide structures identified on CA125 [7]. 
This hypothesis was supported by the study of Patankar et al. where natural killer (NK) cell function 
was found to be inhibited in the presence of CA125 purified from OVCAR-3 cell culture [8]. Cell 
membrane-bound CA125 was subsequently shown to bind directly to NK cells derived from peripheral 
blood of ovarian cancer patients and pregnant women [9]. A potential link between the suppression of 
NK cells in feto-maternal tolerance and the immune evasion of ovarian cancers was therefore  
proposed [9]. Further investigation into the mechanism of interaction revealed that binding was 
established through the sialic acid-binding Ig-like lectin-9 (Siglec-9), an inhibitory receptor expressed 
on NK cells [10,11]. 
Furthermore, the C-terminus of CA125 has been shown to interact specifically with galectin-1 
which, on its own, has been shown to be upregulated in various cancer-derived cell lines [12] 
(reviewed in [13]). Studies have also reported CA125 binding to mesothelin, a 
glycosylphosphatidylinositol-linked cell surface protein [14]. It is hypothesized that this interaction 
may play a role in detachment, attachment and localized invasion that is unique to ovarian cancer 
metastasis [15]. In addition, CA125 was described as a calcium-dependent protease, as the addition  
of EDTA to FPLC-purified CA125 prevented auto-proteolysis [16]. However, the presence of  
other proteins (e.g., proteases) in the high molecular weight CA125 FPLC fraction was not 
investigated. To date, knowledge about many functional aspects of CA125 remains incomplete. 
Further investigations are therefore required to elucidate the role(s) of this molecule in pathological 
and physiological conditions.  
3. Nucleotide and Amino Acid Sequence 
The currently available genomic information on CA125 is based on two autonomous studies 
conducted in 2001 [17,18]. By screening a cDNA library generated using OVCAR-3 mRNA, Yin et al. 
identified a clone with a 5797 base pair (bp) nucleotide sequence [17] (reviewed in [19,20]). Although 
this region translated to a partial CA125 protein, it confirmed and revealed the existence of some key 
features. Importantly, they established the presence of partially conserved tandem repeats and were the 
first to describe the homology to the “sea urchin sperm protein, enterokinase, agrin” (SEA) domain. 
Yin et al. also postulated the existence of a transmembrane domain based upon a cluster of 
hydrophobic residues and a phosphorylation site based on a tyrosine phosphorylation consensus  
motif [17]. Furthermore, O-glycosylation was inferred due to the serine, threonine and proline content 
as well as N-glycosylation due to the asparagine content of the protein. These findings were supported 
and extended on by O’Brien and co-workers [18,21]. Here, a large transcript encoding CA125 was 
sequenced based upon a cyanogen bromide cleavage fragment of CA125 and a translated expressed 
sequence tag [16]. The resultant protein was described in three parts; an amino terminal domain, a 
repeat domain and a carboxy terminal domain (Table 1, Figure 1). The carboxy terminal domain 
reported by O’Brien et al. was homologous to the findings of Yin et al. [17,18,20]. One feature 
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described only by O’Brien was the existence of a potential proteolytic cleavage site at amino acid 
residues 171–181 [18].  
Table 1. Features described from the CA125 amino acid sequence based on the data of 
O’Brien [18,21], Yin [17], Maeda [22] and Berman [23]; Amino acid (aa) number 
(numbering derived from [18]) indicates the position of those residues as they appear 
within the respective domain. bp: base pairs. 
Domain 
Features 
Carboxy Domain Repeat Domain Amino Domain  
Exons 9 5 9 
Nucleotides (bp) 14,000 Single: 1900 50,950 
Cumulative: Unknown 





Poly A Signal 
Potential 
Transmembrane 





Cleavage Sites  
(aa 171–181 [18] and 
aa 35/36 [22]) 
SEA domain 
Cysteine loop (aa 59,79) [23] 






As described previously, the repeat domain consists of partially conserved tandem repeats that are 
156 amino acids in length. The SEA domain was noted to constitute the first 131 amino acids of this 
region [18]. However, the amino acid sequence exhibiting a SEA domain is variable in length as the 
main feature of the consensus sequence is a “strand-strand-helix-strand-strand-helix” secondary 
structure motif and is unaffected by small sequence gaps between these units [24]. Therefore, as most 
CA125 tandem repeats are polymorphic, the SEA domain may not necessarily be 131 amino acids 
long. This is exemplified by the identification of a SEA domain consensus sequence with a length of 
59 amino acids located in the non-tandem repeat region of the C-terminal domain [17]. Furthermore, 
the repeat domain contains a highly conserved methionine at position 24 as well as two highly 
conserved cysteine residues at position 59 and 79 [18]. These cysteine residues in the repeat domain 
were hypothesized by O’Brien to form a 19 amino acid loop to which the M11 antibody binds. 
Additionally, O’Brien demonstrated a loss of binding of the M11 antibody to a recombinant repeat 
domain when digested with Asp-N or Lys-C as this would have disrupted the cysteine loop [18]. 
In the study by O’Brien et al., 45 unique and 15 redundant tandem repeat sequences were  
identified [18]. It was concluded that CA125 consists of at least 60 tandem repeats. However, due to 
difficulties associated with sequencing repeat regions some may be wrongly positioned or unknown, 
leaving the exact number of repeats undefined [18]. Furthermore, O’Brien states that the genome 
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database is deficient in repeat information as repetitive sequences were potentially deleted during the 
compilation process of the human genome [18]. This suggests that the currently available nucleotide 
sequence of CA125 may not be correct. 
The amino terminus was first described as a 1637 amino acid domain coded by 5 exons [17,18]. 
This was later revised by O’Brien et al. where an additional 37,700 nucleotides were sequenced from 
chromosome 19 [21]. Acquisition of the complete amino domain was confirmed by the identification 
of a Kozak translational initiation sequence as well as supporting Northern blot and mRNA expression 
data [21]. The main feature of this domain is the abundance of serine and threonine residues, which 
represent many potential sites of O-glycosylation, and disperse asparagine residues as potential sites of 
N-glycosylation [21].  
Figure 1. Schematic of CA125. (A) A diagrammatic overview of the molecular structure 
of CA125 as described by O’Brien et al. [18,21]; (B) A typical repeat unit of 156 amino 
acids and the possible features assigned to this sequence. At least 60 repeats have been 
identified, of which 45 are unique sequences, giving rise to a minimum domain length of 
9800 aa [18]. Serine/Threonine rich region downstream of SEA domain was unspecified [18], 
O-glycosylation potential of a randomly chosen repeat unit (aa 14,255–14,410) was 
determined by submission to NetOGlyc 3.1 Server [25] (aa 131–156); (C) Carboxy 




Int. J. Mol. Sci. 2012, 13 10573 
 
 
Figure 1. Cont. 
 
The elucidation of the almost complete CA125 nucleotide sequence represented a significant leap in 
understanding. It enabled clarification of known and/or suspected features such as glycosylation 
(amino domain), multivalent antibody binding (repeat domain) as well as anchorage to and release 
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from the membrane (carboxy domain) [12,27]. The findings also raise questions regarding the 
generation of lower molecular weight isoforms. Only the existence of a CA125 precursor protein of 
approximately 400 kDa has been found to exist in the cytoplasm of OVCAR-3 cells prior to protein 
maturation [28]. CA125 variants are also thought to arise from proteolytic cleavage. Proteins such as 
MUC1 have a proteolytic cleavage motif, GSVVV, in their SEA domain [29,30], however the 
presence of a motif with a similar consensus sequence has only been confirmed in one SEA domain of 
CA125 thus far [22]. A cluster analysis of a human CA125 sequence, containing the first 12 tandem 
repeats and a murine homolog to the C-terminus of CA125, was performed by Maeda et al. [22]. 
Interestingly, a DSVLV sequence in the second SEA domain from the cytosolic side of CA125 was 
clustered with the GSVVV sequence. Therefore, it was concluded that proteolytic cleavage might also 
occur in this domain of CA125 [22]. However, the formation of further proteolytic fragments of 
CA125, by the mechanism of the DSVLV or GSVVV sequence, in additional SEA domains has not 
been reported. Furthermore, O’Brien et al. suggested that the formation of alternative splicing products 
of this protein seems unlikely, based on the inherent variation of the five exons encoding for each 
repeat sequence [18]. Therefore, a discrepancy exists between antibody findings of low molecular 
weight isoforms and the protein sequence data (discussed below). 
4. Antigenic Determinants 
Numerous antibodies have been generated against CA125 since the initial discovery in 1981. These 
antibodies are classified as OC125-like (group A), M11-like (group B) or OV197 (group C) depending 
on the antigenic determinant recognized [31]. These antibodies are further subdivided into groups  
A1–A4 (OC125-like), B1/B2 (M11-like) and C1/C2 (OV197-like) [32,33]. It is important to note that 
although there are two antibodies classified as OV197-like, the antigenic recognition behavior of 
OV197 is different to that of 7C12 [32]. Extensive investigation into the epitope recognition of the 
different class antibodies to CA125 has been performed by the International Society of Oncology and 
Biomarkers (ISOBM) TD-1 workshop [31]. Cross-inhibition and immunometric assays have been used 
to examine the various epitopes on CA125 isolated from normal abdominal fluids, cervical mucus,  
cell culture and ascites [32]. From this the importance of antibody class combinations for accurate 
detection of CA125 was revealed. Furthermore, differential antibody interaction with CA125 isolated 
in low-molecular-weight fractions was also highlighted. Here, different immunometric assay 
combinations resulted in different CA125 activity levels in those fractions [32]. It was noted that the 
difference in assay results could be due to the different behavior of the antibody combinations towards 
the low-molecular-weight fractions of CA125 preparations [32]. Conversely, fractions containing  
high-molecular-weight CA125 yielded similar CA125 activity levels regardless of the antibody pair 
used in the immune-assay. As high-molecular-weight forms of CA125 are the major component in 
most samples this phenomenon should, therefore, not interfere with the immunometric assays even if 
the standards used do not have the same composition as the sample [32].  
OC125-like and M11-like antibodies are proposed to detect a cysteine enclosed loop (C-loop) 
structure in the repeat domain [18,31,32] with a paucity of glyco-structures in the immediate  
proximity [18]. Extrapolated from the C-loop of a murine derived CA125 repeat domain homolog, 
Maeda et al. suggested that this antigenic region forms a β-sheet structure [22]. This was later 
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confirmed with a synthesized 21 amino acid long human CA125 antigenic domain [23]. Here, a serine 
in position 8 of the loop was found to be essential for structural formation [23]. However, it is 
important to note that this serine at position 8 is conserved in the repeat sequences, throughout human 
CA125, in only around 25% of the cases. In approximately 60% of repeat sequences a proline is found 
at position 8, which results in random coil formation [23]. 
The fourth report from ISOBM TD-1 workshop described the use of a recombinant sequence of the 
11th repeat from the N-terminus (R11) to test the binding capacity of various OC125-like, M11-like 
and OV197-like antibodies [33]. It was shown that the binding of the various monoclonal antibodies 
differed between the groups and subgroups. Within group A, subgroups A3 and A4 showed high 
binding to R11. Group B also displayed high reactivity with the exception of four investigated  
M11-like antibodies that showed low to no binding [33]. Additionally, group C antibodies had shown 
only little or no reactivity [33]. From those results it was concluded that the poor or absent binding of 
some antibodies towards R11 is unlikely to be due to a disparate sequence of this particular repeat to 
the other +60 repeat sequences, as there are only three main epitope families identified to date [33]. 
This observation was thought to be, more likely, a result of the single R11 repeat not exhibiting an 
optimal conformation as it is no longer in its native context [33]. This was exemplified by the binding 
behavior of OC125, which binds poorly to R11 [33] yet shows strong binding to a recombinant 3 
tandem repeat form of CA125 [34]. 
Furthermore, glycosylation of CA125 has also been shown to be important for high affinity 
antibody binding. Deglycosylation with PNGase F led to lower affinity binding of the OC125 antibody 
to CA125 [7]. However, the exact influence glycosylation has on the binding affinity of the different 
antibody classes to CA125 is unknown. 
5. Forms and Variants 
Several different masses corresponding to CA125 have been reported in the literature. A protein 
with a mass over 1000 kDa as well as proteins with a lower molecular mass ranging from  
200–400 kDa, 130 kDa, 205 kDa and 55 kDa have been observed depending on the source material 
analyzed [35–37] (reviewed in [38]). A number of these studies have also reported a modular structure 
of CA125, which can be broken down into 200 kDa, 70 kDa and 50 kDa species [35,37]. These forms 
of CA125 have been referred to as splice variants, which give rise to amino acid sequences with a 
molecular mass between 49 and 1500 kDa [22,39]. 
However, studies by Lloyd and Yin found no evidence for the low molecular weight products 
reported by other groups using an OVCAR-3 cell line [28,40]. Later they reported a precursor form of 
CA125 of approximately 400 kDa in an OVCAR-3 cell line, from which the mature form of the 
protein becomes assembled [28]. It is noted that only the mature protein form is released into the 
surrounding medium [28]. Additionally, the low molecular weight forms reported by other groups 
were assessed as possible degradation products by using trypsin [28]. This resulted in no defined, 
prominent molecular weight bands on a SDS-PAGE gel [28]. Furthermore, our research has not found 
evidence of low molecular weight forms of CA125 in human ascites [41]. Here, cross-reactivity of the 
employed M11-like and OC125-like antibodies was shown by two-dimensional western-blotting, mass 
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spectrometric identification and spiking experiments. Therefore, the existence of lower molecular 
weight forms of CA125 remains uncertain. 
6. Oligosaccharide Moieties 
Mucins such as CA125 are large proteins associated with extensive glycosylation that is important 
for structure and function (reviewed in [42]). In addition to the contradicting views regarding the 
molecular weight forms of CA125, the types of glycosylation reported are also controversial. Davis et al. 
identified CA125 as protein with, in comparison to other mucins, low carbohydrate content of 24%, 
constituting mostly mannose and N-linked glycans [35], while Hanisch et al. described CA125 as 
consisting of 68% carbohydrates, essentially mannose free and O-linked glycans [43].  
A third view was presented by Nagata et al. in 1991 [44]. They found CA125 to be a 
glycosylphosphatidylinositol (GPI) anchored molecule with N- and O-linked glycan structures [44]. 
Independently, a study by Kui Wong et al. also found N- and O-linked glycans attached to CA125 [7]. 
Interestingly, one identified structure was identical to an unusual glycostructure expressed by 
uromodulin [7,45]. In light of our recent results these contradicting reports may arise from  
cross-reactivity of the M11-like and OC125-like antibodies with other proteins [41]. This may have 
lead to the characterization of proteins that were wrongly assigned as CA125. 
Additionally, aberrant glycosylation of CA125 has been reported for various diseases. The study of 
Pastan et al. demonstrated increased presentation of Lewis y blood group tetrasaccharide (Ley) on 
ovarian cancer tissue compared with normal ovarian tissue [46]. This Ley modification, expressed in 
75% of ovarian cancer tissue specimens, was identified as a part of the CA125 glycan structure [47]. 
Microheterogeneities in CA125 glycosylation may represent a possible diagnostic indicator, according 
to Jankovic et al., as differential glycosylation of CA125 derived from amniotic fluid and OVCAR-3 
cells was demonstrated [48]. Furthermore, Mitic et al. reported differential binding of CA125 to a set 
of sialic acid-binding Ig-like lectins (Siglecs) depending on the source of the protein. A preference for 
Siglec-9 binding was evident for CA125 derived from an OVCAR-3 cell line [49]. Interestingly, this 
interaction has been shown to be necessary for the binding to and subsequent suppression of NK-cell 
function [8–11]. 
7. Mass Spectrometric Identification of CA125 
Isolation of CA125 for the analysis of its molecular features represents a challenge for researchers, 
as routine high resolution methods such as SDS-PAGE are not ideal for very high molecular weight 
analytes. Typically, size exclusion chromatography (SEC) is used for CA125 purification; however the 
separation efficiency is limited and results in cross-contaminations [16]. Additional methods used for 
the prefractionation of CA125 include immuno-precipitation, affinity chromatography or a combination 
of these methods that are associated with similar disadvantages [12,16,28,48,50]. Subsequent 
identification of CA125 in the derived fractions is therefore necessary for reliable downstream 
analysis. However, CA125 identification solely based on antibody probing alone can lead to  
false-positive protein assignment as a result of antibody cross-reactivity [41]. Thus, characterization of 
these secondary proteins may lead to erroneous assignment of molecular attributes to CA125. Several 
studies show that mass spectrometry (MS) offers a suitable solution for independent CA125 
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identification (discussed below). It is, however, notable that the published protein sequence for CA125 
is incomplete [17,18,21]. Although this may result in some peptide identifications being missed by 
search algorithms, mass spectrometric identification of CA125 is a viable approach that can 
complement antibody based identification methods. 
The first peptide mass fingerprinting data on CA125 was described in 2003 where 16 masses, 
corresponding to peptides of a 1148 amino acid form of CA125 from HeLa cells, were detected [12]. 
This enabled the identification of CA125 as a binding protein of galectin-1. In a later study,  
Jankovic et al. identified an approximately 200 kDa form of CA125 in first trimester human placental 
extract based on 36 experimentally detected masses [51]. Similarly, Milutinovic et al. reported 
identification of 46 masses that matched to CA125 in human amniotic fluid [52].  
Tandem mass spectrometric data on CA125 was first reported by Kui Wong et al., confirming the 
identity of CA125 in a purified sample prior to oligosaccharide characterization [7]. Although only a 
single peptide was reported, this identification was supported by peptide mass fingerprinting where 11 
experimentally derived masses were matched to theoretical peptides. Analyses of the tear proteome by 
tandem MS lead to the identification of 491 proteins including CA125 [53]. This was the first mass 
spectrometric data of CA125 that included statistical analysis and associated metadata for eight 
peptides of this protein. However, the molecular weight range of the fraction in which CA125 was 
identified was not stated. Using Fourier-transform ion cyclotron resonance (FT-ICR) tandem mass 
spectrometry Andersch-Bjorkman et al. detected 31 peptides from a 2–3 MDa form of CA125 derived 
from mucus of the human cervical opening [54]. Davies et al. also reported the identification of a high 
molecular weight form of CA125 in human tracheal secretions [55]. Recently, we have also presented 
mass spectrometric data including statistical analysis and metadata of 21 peptides of a high molecular 
weight species of CA125 [41]. These data were used to confirm the identity of CA125 in the ascites of 
ovarian cancer patients as a high molecular weight protein. 
To date, mass spectrometric data of CA125 is still quite rare and seldom reported in a way that 
satisfies the “Minimum Information about a Proteomics Experiment” (MIAPE) standards [56–58], 
even after 2007. MIAPE standards have been implemented to avoid confusion about mass 
spectrometric experiments as well as enhance reproducibility and reliability of MS data. It is evident 
that the quality of mass spectrometric data regarding CA125 varies greatly and the majority of studies 
do not allow for independent assessment. Furthermore, statistical analysis of the MS-generated data is 
seldom presented. This is a major issue, especially for CA125, as the potential for incorrect peptide 
matches rises with increasing length of protein sequence [59]. 
Additionally, matching experimentally found masses to theoretical masses without the usage of 
statistical tools is prone to produce false-positive identifications. Schober et al. demonstrated that 
when a mass accuracy window greater than ± 10 ppm is used, numerous peptides from different 
proteins with similar masses can be assigned to the incorrect protein [60]. This means that CA125 
identification without supporting statistical analysis is unreliable and potentially false-positive.  
8. Conclusion 
CA125 is heavily relied upon for diagnosis and prognosis of epithelial ovarian cancer; however the 
molecular characteristics are poorly understood and are the subject of ongoing investigations. This 
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review summarizes and evaluates the available data regarding the molecular features of CA125. While 
the nucleotide sequence of this protein was independently cloned by two groups and showed an almost 
complete homology between the overlapping parts, other molecular features like predominant type of 
glycosylation and isoforms are not only disputed but mutually exclusive. Although mass spectrometry 
has already been shown to be a valid option to clarify these ambiguous findings, most data generated 
by this method, and published so far, does not satisfy established reporting standards. This review 
highlights the importance of high quality mass spectrometric data to independently verify the identity 
of the investigated protein. This would ensure that CA125 identified by antibody-dependent methods 
are not cross-reactive proteins. Therefore, the ambiguous views on the glycan structure as well as the 
controversial low molecular weight forms can be clarified. This greater understanding may help 
improve established measurement techniques for assaying CA125 serum levels. Alternatively, novel 
detection systems that are independent of antibodies, such as selective reaction monitoring mass 
spectrometry (SRM), could also be applied for CA125 quantitation in patient samples. SRM has 
already been shown to be a feasible approach to quantify proteins in plasma [61]. Furthermore, 
detailed structural information on CA125 will enable the development of new and more refined 
molecularly targeted antibody therapies which already show great clinical potential and warrant further 
research [62–65].  
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